News

Orthovita’s Vitoss scaffolds are marketed specifically for the purpose of providing non-load bearing geometric support during new tissue growth. Aastrom’s tissue repair cells (TRCs), meanwhile, are a mixture

The trial, named RESPOND, will investigate the use of a multipurpose biomarker, Protein C, to be used in connection with the administration of Xigris (drotrecogin alfa [activated]). Under

Orphan drug designation could provide SciClone with seven years of market exclusivity in the US should Zadaxin receive regulatory approval from the FDA for the treatment of malignant

The company said that it will continue to work with FDA to resolve outstanding issues including product labeling and post marketing commitments. In August, the FDA issued an

The completion of enrollment keeps the company on course to report data from this trial during 2006. Antisoma is currently conducting three separate phase II trials with AS1404

The company’s scientists found that these adult stem cells were able to differentiate into most tissues and organs of the body – including spermatogonia. The company further said

The trial was evaluating temsirolimus in combination with Femara, Novartis’ currently approved breast cancer therapy. The study compared the combination of the drugs versus Femara alone. This decision

Ceflatonin is the first of a new class of novel drugs that induces programmed cell death and inhibits the formation of new blood vessels that support the tumor.

The company said that initial activity will commence in such areas as addiction, cognition, anxiety, depression and stress-related disorders, but is expected to include several other disease areas.